Tergene Biotech

Hyderabad, India Founded: 2008 • Age: 18 yrs Acquired By Aurobindo Pharma
Bio-conjugate technologies for bacterial vaccines and conjugates are developed.

About Tergene Biotech

Tergene Biotech is a Healthcare company based in Hyderabad (India) founded in 2008, and was acquired by Aurobindo Pharma in February 2025. Bio-conjugate technologies for bacterial vaccines and conjugates are developed. Its Indian entity Tergene Biotech Limited reported revenue of β‚Ή4.46 Cr. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.

Company details

Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed technologies for the production of various vaccines and biosimilars such as Acellular Pertussis (ACP) vaccine, Haemophilus influenza type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Terinase - a thrombolytic enzyme are some of its developed technologies. The vaccines are currently under advanced stage of development include a multivalent pneumococcal vaccine and Meningococcal vaccine. It also offers a full range of contract research services from bioprocess development to manufacturing to approval of the finished product.

  • Headquarters Hyderabad, India
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website tergene.com
  • Acquired by Aurobindo Pharma (Feb 2025)
  • Legal Name Tergene Biotech Limited
  • Date of Incorporation 07 Mar, 2008
  • Jurisdiction Hyderabad, Telangana, India
Key Metrics
  • Annual Revenue
    ₹4.46 Cr

    FY 2026 · +4892% YoY

  • Net Loss
    -₹81.8 Lakh

    FY 2026 · -18% margin

  • EBITDA
    ₹3.86 Cr

    FY 2026 · 86% margin

  • Investors
  • Acquired by

Funding Insights of Tergene Biotech

  • Total Rounds 2
  • Investors Count 2

All 2 funding rounds of Tergene Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2013Grant––
Jun 2012Grant––
Valuation history

3 investors in total: 3 institutional.

Investors in Tergene Biotech

Tergene Biotech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Aurobindo Pharma, Department of Biotechnology and BIRAC.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Business incubation services are provided across multiple sectors.
birac.nic.inDelhi, India
Biotechnology research, guidelines, and funding by the Government of India.
1986dbtindia.gov.inDelhi, India
Generic biocatalytic solutions are provided for pharmaceutical applications.
1986aurobindo.comHyderabad, India
Premium access

Investor details for Tergene Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Tergene Biotech Limited (Tergene Biotech)

Tergene Biotech Limited is the primary company behind Tergene Biotech. The boards of the 2 registered companies of Tergene Biotech currently have 14 directors; the longest-serving is Venkata Ramprasad Reddy Penaka, appointed in 1992. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Venkata Ramprasad Reddy Penaka
DIN 01284132
Director30 Dec 199233 yrs 10 moAurobindo Pharma Ltd
Nityananda Reddy Kambam
DIN 01284195
Managing Director30 Dec 199233 yrs 10 moAurobindo Pharma Ltd
Sarath Chandra Reddy Penaka
DIN 01628013
Director27 Sep 200719 yrs 1 moAurobindo Pharma Ltd
Mosuvan Kuppusamy
DIN 00066698
Director07 Mar 200818 yrs 8 moTergene Biotech Limited
Kuppusamy Sathyan
DIN 01493015
Director07 Mar 200818 yrs 8 moTergene Biotech Limited
Madan Mohan Reddy Mettu
DIN 01284266
Whole-time director01 Jan 201313 yrs 10 moAurobindo Pharma Ltd
Sivakumaran Meenakshisunderam
DIN 01284320
Director01 Apr 201511 yrs 7 moTergene Biotech Limited
Santhanam Subramanian
DIN 03516515
Director26 Aug 201610 yrs 2 moTergene Biotech Limited
Girish Paman Vanvari
DIN 07376482
Director05 Nov 20206 yrsAurobindo Pharma Ltd
Santanu Mukherjee
DIN 07716452
Director09 Feb 20233 yrs 9 moAurobindo Pharma Ltd
Umesh Krishnamoorthy
DIN 10195095
Director28 Jun 20233 yrs 4 moTergene Biotech Limited
Satakarni Makkapati
DIN 09377266
Director09 Nov 20233 yrsAurobindo Pharma Ltd
Mangalam Ramasubramanian Kumar
DIN 03628755
Director01 Apr 20242 yrs 7 moAurobindo Pharma Ltd
Punita Kumar Sinha
DIN 05229262
Director09 Feb 20269 moAurobindo Pharma Ltd

Financials of Tergene Biotech

Figures of Tergene Biotech Limited, the primary company behind Tergene Biotech, for FY 2026. Revenue was ₹4.46 Cr (+4892% year on year). Net loss was -₹81.8 Lakh (-18% margin). EBITDA was ₹3.86 Cr (86% margin). Revenue has grown at a compounded annual rate of -12% over three years and +45% over five years.

  • ₹4.46 CrRevenue · FY 2026 · +4892% YoY
  • -₹81.8 LakhNet loss · -18% margin
  • ₹3.86 CrEBITDA · 86% margin
  • ₹47.15 CrPaid-up capital
  • -12%Revenue CAGR, 3 years
  • +45%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Tergene Biotech Limited are on its company page.

Premium access

Detailed financial statements for Tergene Biotech

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Tergene Biotech

4 dated milestones of Tergene Biotech across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tergene Biotech is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Grant,.
  4. Exit Acquired by Aurobindo Pharma.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tergene Biotech

Premium access

Complete news archive for Tergene Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tergene Biotech

Tergene Biotech was founded in 2008 and raised its 1st funding round 4 years after it was founded.

Tergene Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

The primary company behind Tergene Biotech, Tergene Biotech Limited, reported revenue of β‚Ή4.46 Cr for FY 2026, up 4892% year on year.

Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed technologies for the production of various vaccines and biosimilars such as Acellular Pertussis (ACP) vaccine, Haemophilus influenza type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Terinase - a thrombolytic enzyme are some of its developed technologies. The vaccines are currently under advanced stage of development include a multivalent pneumococcal vaccine and Meningococcal vaccine. It also offers a full range of contract research services from bioprocess development to manufacturing to approval of the finished product.

Tergene Biotech has 3 investors. Key investors include Aurobindo Pharma, Department of Biotechnology, and BIRAC.

Tergene Biotech is associated with 2 legal entities: Tergene Biotech Limited, Aurobindo Pharma Ltd.

Yes. Tergene Biotech was acquired by Aurobindo Pharma in February 2025.

The legal entities of Tergene Biotech currently have 17 directors, including Umesh Krishnamoorthy, Mosuvan Kuppusamy, Sivakumaran Meenakshisunderam and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available